Axinn Advised Thermo Fisher on $1.85B Acquisition of PeproTech, Inc.
January 5, 2022
Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its approximately $1.85 billion acquisition of PeproTech, Inc., a leading developer and manufacturer of recombinant proteins. The deal closed on December 30, 2021. The Axinn antitrust team included partners John Harkrider and Mark Alexander, who were assisted by Craig Minerva, Tasneem Chowdhury, Megan Walden, and Kyle Sherwood.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
AHLA Health Care Transactions Program 2026
Sponsorship
Antitrust
IPWatchdog Sixth Annual Live Conference
Speaking Engagement
Intellectual Property
ABA White Collar Crime Institute 2026
Speaking Engagement
Back to the Well: FDA’s Draft Guidance on New Clinical Investigation Exclusivity
Axinn Viewpoints
Intellectual Property
Mother, May I? The Use of Prior Approval Requirements in Merger Settlements
Podcast
Antitrust
The Curtain Rises Again on FTC Act Section 5
Axinn Viewpoints
Jeny Maier Named Finalist for Managing Partner of the Year in 2026 Women, Influence & Power in Law Awards
Awards & Recognitions
DOJ Serves Up a Statement of Interest with a Side of Fries
Axinn Viewpoints
Antitrust
GCR Live Cartels: 2026
Speaking Engagement
Antitrust
PLI Fundamentals of Taking and Defending Depositions 2026
Speaking Engagement
Litigation & Trials